Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. Measure Specifications can be accessed through the Quality Portal ( QPort), which requires a log-in.įor questions related to the release of these quality measures, please contact the NCDB at Primary Site These performance rates will be reviewed during site visits beginning in 2022.

Standard 7.1 states that each calendar year, the expected performance rate is met for each of the selected accountability and quality improvement measures as defined by the CoC, and the cancer committee of each accredited program monitors the selected accountability measures.įor 20, the program’s performance rate for this Standard is expected to be equal to or greater than the expected rate specified by the CoC, or the upper confidence interval should cross that expected rate for the nine (9) measures listed below. In the Commission on Cancer (CoC) Optimal Resources for Cancer Care (2020 Standards), Standard 7.1 Accountability and Quality Improvement Measures requires CoC-accredited cancer programs to treat cancer patients according to nationally accepted accountability and quality improvement measures indicated by the CoC and included in the Rapid Cancer Reporting System (RCRS) tool.

Coc coc browser for mac